AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15299060
Drug: Acetazolamide (ACZ)
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetazolamide (ACZ) administered intravenously at a dosage of 1 g
Trial: 15299060
Drug: Continuous-infusion H(2)(15)O
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous-infusion H(2)(15)O PET
Trial: 9354317
Drug: Tedisamil (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tedisamil (100 mg twice daily)
Trial: 2656775
Drug: Atenolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (50 mg twice daily)
Trial: 9354317
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Tedisamil and Atenolol
Trial: 9354317
Drug: Tedisamil alone
RxNorm normalized name: tedisamil
DrugBank: Tedisamil (DB06200)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tedisamil alone and in combination with Atenolol
Trial: 8308936
Drug: Buspirone 10
RxNorm normalized name: busPIRone 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone 10 mg t.i.d.
Trial: 8308936
Drug: Placebo 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 10 mg t.i.d.
Trial: 29725790
Drug: Active, Linkage,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active, Linkage, Engagement, Retention and Treatment (ALERT) specialist for outreach and health coaching
Trial: 22947269
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment supported by self‐monitoring (pro‐active counseling, pedometer, weighing scale, blood pressure device)
Trial: 22947269
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment without self‐monitoring
Trial: 22947269
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment supported by self‐monitoring
Trial: 1204278
Drug: Nabilone 1
RxNorm normalized name: nabilone 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabilone 1 mg
Trial: 7569458
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg od plus amoxicillin 500 mg tid (group A)
Trial: 7569458
Drug: Bismuth subsalicylate
RxNorm normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bismuth subsalicylate 260 mg bid, metronidazole 250 mg tid and amoxicillin 500 mg tid (group B)
Trial: 1943411
Drug: Hypercaloric parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypercaloric parenteral nutrition
Trial: 1943411
Drug: Hypocaloric parenteral
RxNorm normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypocaloric parenteral nutrition
Trial: 7026255
Drug: Captopril (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (1 mg/kg body weight)
Trial: 30664267
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF), 12 doses of 300 μg each in 28 days
Trial: 28508697
Drug: Topical estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical estrogen (GI)
Trial: 28508697
Drug: Topical genistein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical genistein (GII)
Trial: 8510706
Drug: Diazepam (0.33
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (0.33 mg/kg) administered orally every eight hours during febrile illnesses
Trial: 8510706
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered orally every eight hours during febrile illnesses
Trial: 8510706
Drug: Diazepam (in
RxNorm normalized name: diazepam (in soybean oil) 5 mg/mL INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (in children who had seizures while receiving the medication)
Trial: 8510706
Drug: Diazepam (among
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (among children who took at least one dose)
Trial: 3499163
Drug: Fasting and
RxNorm normalized name: norgestimate and ethinylestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting and 15 ml aluminium hydroxide gel
Trial: 3499163
Drug: Postprandial and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postprandial and 15 ml aluminium hydroxide gel
Trial: 3499163
Drug: Fasting and
RxNorm normalized name: norgestimate and ethinylestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting and 15 ml aluminium and magnesium hydroxide gel
Trial: 3499163
Drug: Postprandial and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postprandial and 15 ml aluminium and magnesium hydroxide gel
Trial: 23374879
Drug: Physical exercise
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical exercise without a clear treatment rationale
Trial: 23374879
Drug: Physical exercise
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical exercise with treatment rationale
Trial: 23374879
Drug: Behavioural activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioural activation with treatment rationale
Trial: 23374879
Drug: Behavioural activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioural activation without a clear treatment rationale
Trial: 23374879
Drug: Waiting list
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting list control group with delayed treatment
Trial: 23374879
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups (including relapse prevention program)
Trial: 19325484
Drug: Early antifungal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early antifungal therapy
Trial: 17543895
Drug: Chronic methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic methylphenidate (MPH) 0.3 mg/kg/dose
Trial: 17543895
Drug: Chronic methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic methylphenidate (MPH) 0.6 mg/kg/dose
Trial: 8004358
Drug: 2.7 g
RxNorm normalized name: Magnesium 420 MG/2.7 GM Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.7 g 3‐sn‐polyenylphosphatidylcholine (PPC) daily, orally for 2 months
Trial: 2682593
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg Org 3770 (ORG)
Trial: 2682593
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg diazepam (DZ)
Trial: 2682593
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of AMI and DZ
Trial: 2682593
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ORG and DZ
Trial: 28973076
Drug: Lutein and
RxNorm normalized name: ICaps Lutein and Omega-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutein and zeaxanthin dietary supplementation (2 daily capsules) for 6 months
Trial: 28254122
Drug: Cardiac Resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac Resynchronization Therapy (CRT-ON)
Trial: 21112898
Drug: Optimal Medical
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal Medical Therapy (CRT-OFF)
Trial: 15078238
Drug: Active nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active nicotine patch (AP, 15 mg daily, n = 100)
Trial: 15078238
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch (PP, n = 100)
Trial: 16966390
Drug: Ketamine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (1 mg/kg) plus midazolam (0.1 mg/kg; max: 2.5 mg)
Trial: 16966390
Drug: Nitrous oxide
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrous oxide (50%)/oxygen (50%) plus hematoma block (2.5 mg/kg of 1% buffered lidocaine)
Trial: 1743624
Drug: CHOEP (cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHOEP (cyclophosphamide 750 mg/m2 iv d 1, doxorubicin 50 mg/m2 iv d 1, vincristine 2 mg iv d 1, etoposide 100 mg/m2 iv d 3‐5, prednisolone 100 mg po d 1‐5)
Trial: 1743624
Drug: hCHOP alternating
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCHOP alternating with IVEP (cyclophosphamide 1200 mg/m2 iv d 1, doxorubicin 40 mg/m2 iv d 1 + 2, vincristine 2 mg iv d 1, prednisolone 100 mg po d 1‐5; ifosfamide 1500 mg/m2 iv d 1‐5, vindesine 3 mg/m2 iv d 1, etoposide 120 mg/m2 iv d 3‐5, prednisolone 100 mg po d 1‐5)
Trial: 7075652
Drug: Alinidine 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alinidine 40 mg orally
Trial: 26524223
Drug: Capacitive mode
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capacitive mode of 448 kHz radiofrequency therapy
Trial: 26524223
Drug: Resistive mode
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistive mode of 448 kHz radiofrequency therapy
Trial: 18640992
Drug: Group 1
RxNorm normalized name: Chlamydophila psittaci biogroup 1 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 (morphine 1 mg/ml, nalbuphine 0 mg/ml)
Trial: 18640992
Drug: Group 2
RxNorm normalized name: Chlamydophila psittaci biogroup 2 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2 (morphine 0.75 mg/ml, nalbuphine 0.25 mg/ml)
Trial: 18640992
Drug: Group 3
RxNorm normalized name: Chlamydophila psittaci biogroup 3 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 3 (morphine 0.5 mg/ml, nalbuphine 0.5 mg/ml)
Trial: 18640992
Drug: Group 4
RxNorm normalized name: Chlamydophila psittaci biogroup 4 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 4 (morphine 0.25 mg/ml, nalbuphine 0.75 mg/ml)
Trial: 18640992
Drug: Group 5
RxNorm normalized name: Chlamydophila psittaci biogroup 5 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 5 (morphine 0 mg/ml, nalbuphine 1 mg/ml)
Trial: 12809966
Drug: Ritonavir 600
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir 600 mg
Trial: 12809966
Drug: Escitalopram 20
RxNorm normalized name: escitalopram 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram 20 mg and Ritonavir 600 mg
Trial: 1848170
Drug: Single intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous injection of inulin (70 mg/kg over 5 min)
Trial: 1848170
Drug: Single injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection method
Trial: 30986760
Drug: Coloxyl with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coloxyl with senna +20 ml lactulose BD commencing on day 3 (Regimen B)
Trial: 30986760
Drug: Coloxyl with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coloxyl with senna tablets +20 ml lactulose BD commencing on day 6 (Regimen C)
Trial: 17187586
Drug: ATI-7505 20
RxNorm normalized name: ATI-355
DrugBank: ATI-355 (DB17923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATI-7505 20 mg t.i.d.
Trial: 17187586
Drug: ATI-7505 10
RxNorm normalized name: ATI-355
DrugBank: ATI-355 (DB17923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATI-7505 10 mg t.i.d.
Trial: 17187586
Drug: ATI-7505 10
RxNorm normalized name: ATI-355
DrugBank: ATI-355 (DB17923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATI-7505 10 and 20 mg t.i.d.
Trial: 16318050
Drug: Lornoxicam (xefocam,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam (xefocam, 16 mg/day)
Trial: 16318050
Drug: Ketorolac (ketanov,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac (ketanov, 60-90 mg/day)
Trial: 16318050
Drug: Ketoprofen/ketonal (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen/ketonal (200 mg/day)
Trial: 16318050
Drug: Ketoprofen/artrozilene (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen/artrozilene (320 mg/day)
Trial: 2366136
Drug: Penicillin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penicillin (10 million units intravenously) and tetracycline (0.25 g intramuscularly) for 12 hours
Trial: 2366136
Drug: Penicillin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penicillin (10 million units intravenously) and tetracycline (0.25 g intramuscularly) for 12 hours followed by oral ampicillin (2 g) and tetracycline (1.5 g) per day for 60 hours
Trial: 639708
Drug: Furosemide (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (80 mg, single daily dose) given on the 12th, 13th, and 14th day of digoxin treatment
Trial: 639708
Drug: Simultaneous administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous administration of furosemide with beta-methyl-digoxin
Trial: 639708
Drug: Furosemide given
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide given ten hours after the last digoxin dose
Trial: 31262691
Drug: Levothyroxine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine treatment (group B2)
Trial: 31262691
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (group B1)
Trial: 29045983
Drug: BATHE intervention
RxNorm normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BATHE intervention (daily for five days or until discharge)
Trial: 25496178
Drug: BNO 1016
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNO 1016 (3 × 160 mg daily for 15 days)
Trial: 25496178
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 × placebo daily for 15 days)
Trial: 23808982
Drug: Apixaban (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban (10 mg twice daily for 7 days, followed by 5 mg twice daily for 6 months)
Trial: 23808982
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (subcutaneous enoxaparin, followed by warfarin)
Trial: 21981441
Drug: AWT(®) treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AWT(®) treatment with CELLACTOR(®) SC1 device, 8 sessions over 4 weeks
Trial: 21981441
Drug: AWT(®) treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AWT(®) treatment
Trial: 20112520
Drug: Sodium fluoride
RxNorm normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium fluoride (NaF) administered for 6 months prior to stapedectomy.
Trial: 20112520
Drug: Stapedectomy without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stapedectomy without sodium fluoride (NaF) administration.
Trial: 11642675
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIG) 400 mg/kg body weight, total 30-45 g, administered in the follicular phase of a planned pregnancy, with a booster dose upon pregnancy diagnosis.
Trial: 8436740
Drug: Intravenous urokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous urokinase alone
Trial: 8436740
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of intravenous urokinase and rt-PA
Trial: 26615328
Drug: Nanoliposomal irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nanoliposomal irinotecan monotherapy
Trial: 24849843
Drug: Response-adaptive randomization
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Response-adaptive randomization scheme with minimal sufficient balancing design for baseline covariates and a cap on treatment allocation ratio shift.
Trial: 24849843
Drug: Control of
RxNorm normalized name: A replication-competent adenovirus type 5 in which the E1A and E1B genes are under the control of a human telomerase reverse transcriptase (hTERT) and IRES, respectively.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control of important covariate imbalance and protection of treatment allocation randomness.
Trial: 18481113
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A (CSA) 150 mg/m(2) orally to achieve trough levels of 120-180 ng/ml
Trial: 18481113
Drug: Cyclophosphamide pulses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide pulses (CPH) 500 mg/m(2) per month intravenous
Trial: 16136855
Drug: RSR13 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSR13 (100 mg/kg)
Trial: 2251872
Drug: Acellular pertussis
RxNorm normalized name: Acellular pertussis vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular pertussis vaccine with pertussis toxoid
Trial: 2251872
Drug: Acellular pertussis
RxNorm normalized name: Acellular pertussis vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular pertussis vaccine with pertussis toxoid and filamentous haemagglutinin
Trial: 31091754
Drug: Collagen peptide
RxNorm normalized name: Procollagen peptide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagen peptide supplementation (15 g daily)
Trial: 22234928
Drug: Aripiprazole (ARIP;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (ARIP; 5-30 mg/day)
Trial: 22234928
Drug: Ziprasidone (ZIP;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone (ZIP; 40-160 mg/day)
Trial: 17875084
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E at a dose of 100 mg/day for 3 months
Trial: 16213237
Drug: Home-based physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based physical therapy (PT) group (n=13)
Trial: 31532959
Drug: Polypill (atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypill (atorvastatin 10 mg, amlodipine 2.5 mg, losartan 25 mg, hydrochlorothiazide 12.5 mg)
Trial: 21837534
Drug: Tamsulosin 0.4
RxNorm normalized name: tamsulosin 0.4 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.4 mg once daily plus phloroglucinol
Trial: 21837534
Drug: Doxazosin 4
RxNorm normalized name: doxazosin 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin 4 mg plus phloroglucinol
Trial: 21837534
Drug: Phloroglucinol 240
RxNorm normalized name: phloroglucinol
DrugBank: Phloroglucinol (DB12944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phloroglucinol 240 mg daily (Control Group)
Trial: 19671145
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy (1-hour session, 4 times a week for 10 weeks) plus pharmacological therapy
Trial: 19671145
Drug: Pharmacological therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological therapy only
Trial: 17067857
Drug: Re-randomization for
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Re-randomization for optimal dosing
Trial: 17067857
Drug: Re-randomization for
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Re-randomization for optimal dose-scheduling
Trial: 17067857
Drug: Re-randomization for
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Re-randomization for salvage therapy
Trial: 17067857
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of treatment trials
Trial: 11737692
Drug: Griseofulvin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Griseofulvin (20 mg/kg/day for 6 weeks)
Trial: 11737692
Drug: Terbinafine (>
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine (> 40 kg: 250 mg; 20-40 kg: 125 mg; < 20 kg: 62.5 mg for 2-3 weeks)
Trial: 11737692
Drug: Itraconazole (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole (5 mg/kg/day for 2-3 weeks)
Trial: 11737692
Drug: Fluconazole (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (6 mg/kg/day for 2-3 weeks)
Trial: 9415509
Drug: Lamotrigine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine (400 mg)
Trial: 3631772
Drug: Terbutaline inhaled
RxNorm normalized name: terbutaline Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline inhaled with a tube spacer
Trial: 3631772
Drug: Terbutaline inhaled
RxNorm normalized name: terbutaline Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline inhaled without a tube spacer (conventional inhaler)
Trial: 31076466
Drug: Online acceptance
RxNorm normalized name: FILTER,SUCTION,INLINE #FHBF200S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online acceptance and commitment therapy (ACT) intervention, 8 sessions over 8 weeks
Trial: 25753087
Drug: Transdermal Fentanyl
RxNorm normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transdermal Fentanyl patches